Host-directed therapies for improving poor treatment outcomes associated with the middle east respiratory syndrome coronavirus infections
Open Access
- 10 September 2015
- journal article
- editorial
- Published by Elsevier BV in International Journal of Infectious Diseases
- Vol. 40, 71-74
- https://doi.org/10.1016/j.ijid.2015.09.005
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirinScientific Reports, 2013
- Research as a Part of Public Health Emergency ResponseNew England Journal of Medicine, 2013
- State of Knowledge and Data Gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in HumansPLoS Currents, 2013
- Statins as a Novel Therapeutic Strategy in Acute Lung InjuryPulmonary Circulation, 2012
- Broad-Spectrum Antiviral TherapeuticsPLOS ONE, 2011
- Distinct Severe Acute Respiratory Syndrome Coronavirus-Induced Acute Lung Injury Pathways in Two Different Nonhuman Primate SpeciesJournal of Virology, 2011
- Selective Depletion of CD4+CD25+Foxp3+ Regulatory T Cells by Low-Dose Cyclophosphamide Is Explained by Reduced Intracellular ATP LevelsCancer Research, 2010
- Anti-inflammatory Agents: Present and FutureCell, 2010
- Mitochondrial Respiratory Complex I Regulates Neutrophil Activation and Severity of Lung InjuryAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Superantigen-induced corticosteroid resistance of human T cells occurs through activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK-ERK) pathwayJournal of Allergy and Clinical Immunology, 2004